DEG is proud to have supported Finnegan and it’s client AstraZeneca in their trial win covering its $3.5 billion diabetes drug patent

in News

On February 3, 2017, Judge Gregory M. Sleet found in favor of AstraZeneca’s patents covering its diabetes drugs Onglyza and Kombiglyze. U.S. District Judge of Delaware ruled that five generic makers failed to show that two asserted claims of AstraZeneca AB’s U.S. Patent Number RE44,196 are invalid as obvious in light of prior art, saying their analysis was flawed. The case is AstraZeneca AB v. Aurobindo Pharma Ltd. et al., case number 1:14-cv-00664.https://www.law360.com/articles/887798/astrazeneca-prevails-in-trial-over-diabetes-drug-patent